Back to Search
Start Over
Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study.
- Source :
-
Thrombosis and haemostasis [Thromb Haemost] 2000 Jul; Vol. 84 (1), pp. 4-8. - Publication Year :
- 2000
-
Abstract
- Combined oral contraceptives (OC) are known to increase the risk of venous thromboembolism. The aim of this randomized, cycle-controlled, cross-over study in 28 healthy volunteers was to assess potential differences between the effects of an OC containing 150 microg levonorgestrel (as representative of the so-called second generation OC) and an OC containing 150 microg desogestrel (as representative of the third generation OC) in combination with 30 microg ethinylestradiol on several coagulation factors and markers of thrombin formation. All participants used each OC for two cycles, and were switched to the other OC after a washout period of two menstrual cycles. The plasma concentrations of factors II, VII, X, and fibrinogen significantly increased during use of both the levonorgestrel- and desogestrel-containing OC's. The plasma concentrations of factor VIII increased, and of factor V decreased, changes which only reached statistical significance during the use of the desogestrel-containing OC. During exposure to the desogestrel-containing OC, as compared with the levonorgestrel-containing OC, both factor VII and factor II showed a greater increase (FVII: 32% and 12% respectively; p <0.0001; FII: 16% and 12% respectively; p = 0.048), whereas factor V showed a greater decrease (-11% and -3% respectively; p = 0.010). Only one of the markers for ongoing coagulation (prothrombin fragment 1+2) showed a significant increase during OC use, whereas concentrations of thrombin-antithrombin complexes and soluble fibrin remained unchanged. For these markers, there was no difference between the tested OC's. We conclude that there are differences between the effects of levonorgestrel and desogestrel-containing OC's on some coagulation factors. Whether these changes provide a biological explanation for the reported differences in venous thromboembolic risk is as yet unclear. The real challenge now becomes to define a pattern of changes in the various systems which, if affected simultaneously, may tip the hemostatic balance towards a prethrombotic state and may lead to overt clinical venous thromboembolism.
- Subjects :
- Adolescent
Adult
Antithrombin III analysis
Biomarkers
Blood Coagulation Factors analysis
Contraceptives, Oral, Combined adverse effects
Contraceptives, Oral, Hormonal adverse effects
Cross-Over Studies
Desogestrel administration & dosage
Desogestrel adverse effects
Ethinyl Estradiol administration & dosage
Ethinyl Estradiol adverse effects
Female
Fibrinogen analysis
Humans
Levonorgestrel administration & dosage
Levonorgestrel adverse effects
Peptide Fragments analysis
Peptide Hydrolases analysis
Prothrombin analysis
Risk Factors
Thrombophilia blood
Blood Coagulation drug effects
Contraceptives, Oral, Combined pharmacology
Contraceptives, Oral, Hormonal pharmacology
Desogestrel pharmacology
Ethinyl Estradiol pharmacology
Levonorgestrel pharmacology
Thrombin biosynthesis
Thrombophilia chemically induced
Venous Thrombosis epidemiology
Subjects
Details
- Language :
- English
- ISSN :
- 0340-6245
- Volume :
- 84
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Thrombosis and haemostasis
- Publication Type :
- Academic Journal
- Accession number :
- 10928461